Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NYjmcphWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fkc|DjiJNzMECwJO69dQ>? MWCyOEBpyqB? NYDMXmlscW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVGyOlA5QDdzMR?=
POLK WT MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\YRVFKSzVyPUGxMlfjiIoEsfMAjVEvP8LizszN M3nielI3ODNzNECw
POLK KO NI\zXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?= NIe0fo8zPjB|MUSwNC=>
POLK CD M{LJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XHcWlEPTB;NT61PgKBkcLz4pEJNU4xOMLizszN NHXRO|AzPjB|MUSwNC=>
RLE/Abca3 NFnIRoNHfW6ldHnvckBCe3OjeR?= NYrJfYFYOC52wrFOwG0> NGXQc3gyPDUEoHi= MUPpcoR2[2W|IHGgcY9zeGixbH;nbYNidCClaHHu[4Uh\nKxbTDldIl1cGWuaXHsMYxqc2VibX;ydIhwdG:peTD0c{BiKHerZHWsJJNxemWjZD3veZQhdW:{cHjvcI9ogcLi MVqyOVc3ODV|OB?=
PMCs MVTGeY5kfGmxbjDBd5NigQ>? M{DNW|AvOeLCk{NCpO69\y:vbB?= M4\nN|I1yqCq MXXjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? MmTLNlU2QTV4NEK=
PMCs Mnv5SpVv[3Srb36gRZN{[Xl? MkjsNE4zyqEQvHevcYw> NHLi[G4zPOLCk{eyxsBp M4DuSolv\HWlZYOgbY5kemWjc3XzJIlvKH[rbXXueIlvKGGwZDFOtU1UVUFicILveIVqdg>? MVmyOVU6PTZ2Mh?=
PMCs M2T0UWZ2dmO2aX;uJGF{e2G7 MY[wMlLDqM7:Zz;tcC=> NV;XXmcyPzJiaB?= NWjjPFlPcW6mdXPld{Bl\WO{ZXHz[ZMhcW5iY4n0c4tmemG2aX6tPEBidmRiRT3jZYRp\XKrbjDwdo91\Wmw MnPzNlU2QTV4NEK=
PMCs NWHlcoh[TnWwY4Tpc44hSXO|YYm= M{HsblAvOsLizsznM41t NUnl[4dlOTJxMkSvOFghcA>? NX7LZ|J{cW6lcnXhd4V{KGOnbHygcYloemG2aX;u NYHnfIVKOjV3OUW2OFI>
IMR-32 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofLO{426ojUMUKwJOK2\y:vbB?= M2XWT|Ez6ojUNEigbC=> Mmn2TWM2OD14MDFCuYcwdWxiYYSgeIhmKGWwZDDv[kAzPCCqcoOgc4YhcW6ldXLheIlwdg>? NX7sTIZEOjV3M{[zOFU>
HT1080 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PW[VEh|ryP M2GzZ|I1KGkEoB?= NUThZWRvdGWjZIOgeI8h[SCJMj;NJIRmdGG7 MnjaNlU2OTh7NkG=
HT1080 NVPYWplITnWwY4Tpc44hSXO|YYm= M4nPdVEh|ryP NGHBS3UzPCCqwrC= NIr1c2xqdmS3Y3XzJIEheG:2ZX70JIdtd2KjbDDEUmEh\GGvYXflJJJme3CxboPl M3fLTFI2PTF6OU[x
HDFn NH7odmJEgXSxdH;4bYNqfHliQYPzZZk> M4m5OVczKGh? M{PJeGlEPTB;OT6zNUXDqA>? MVGyOVI4Pjd7Mh?=
THP-1 NXjo[oxuS3m2b4TvfIlkcXS7IFHzd4F6 MojzO|IhcA>? NFrFWINKSzVyPUSuO|cm MVOyOVI4Pjd7Mh?=
HT-29 M{H0dmN6fG:2b4jpZ4l1gSCDc4PhfS=> MlvJO|IhcA>? M3zlVWlEPTB;MUGuOFkm NHn3NpozPTJ5Nke5Ni=>
HCT116  M2n0eGN6fG:2b4jpZ4l1gSCDc4PhfS=> M37JflczKGh? NXS0NXF[UUN3ME2xNU4{PCV? NF7yclgzPTJ5Nke5Ni=>
A431 NYnrVmxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jIeVUxNTJyMDDJWS=> NUHtU5h3PDkkgJno NUj4SFlRcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NIjtUYgzPTFyMUK5PS=>
T24 M3zqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG1NE0zODBiSWW= M3HvRVQ56oDLaB?= MmmybY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M2rGNlI2OTBzMkm5
AY-27  MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVW1NE0zODBiSWW= NInz[3U1QOLCiXi= NIn3ZWhqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NHi5NJAzPTFyMUK5PS=>
A549 MljpSpVv[3Srb36gRZN{[Xl? NHrTRpcyKML3Zz;tUOKh M4ewPFAuPDhiaB?= NXz0WHNCcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? M1nMNFI1QTZ|NkO1
MLE12 Ml\BSpVv[3Srb36gRZN{[Xl? MkDKNUDDvWdxbV|CpC=> NHjpbo0xNTR6IHi= MoHobY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> NVPJPFZoOjR7NkO2N|U>
Jurkat MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPBeIlpOjEkgJpOwI0> NYDuZ|k6OjUkgJnoxsA> NUPzcppJ[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? MmfHNlQ6OTZ6OUO=
HeLa  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:2VGlEPTB;MUCuNuKh|ryP NUSzWG5TOjR5M{KzPVc>
C18-4 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDPR493OC1zMECg{txO MnS5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXrXOJNGOjR3N{G5PFI>
BMG-1  Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT4Z441OC96MNMg{txoN21? M4HCPFPDqGh? MWLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmfnNlM6ODZ5Mk[=
A459 M3rTRWFxd3C2b4Ppd{BCe3OjeR?= NFfZb|AyOCCvVR?= MYO0PEBp MY\pcoR2[2W|IHHwc5B1d3Orcx?= NHnXVGgzOzlyMke2Oi=>
MOCK NFf5ZZlCeG:ydH;zbZMhSXO|YYm= MoXWNVAhdVV? NHv5OHU1QCCq M1fPdYlv\HWlZYOgZZBweHSxc3nz Ml3wNlM6ODJ5Nk[=
MMP1 NIPBNIRCeG:ydH;zbZMhSXO|YYm= MmDlNVAhdVV? M4e4c|Q5KGh? NYjISIt1cW6mdXPld{BieG:ydH;zbZM> MUSyN|kxOjd4Nh?=
A549 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[yNFAh|ryP NGrLVWUzPCCqwrC= NFvHOXdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NELobnczOzhyNUe5Ny=>
HCT-116 NHHIeYFCeG:ydH;zbZMhSXO|YYm= NIHtWWU{NzdwNT:xOUDPxGdxbXy= NF;wZnk1QCCq Mn7ZdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NWjWdFZSOjN5MEi2Olg>
HeLa NVm4fGQ6SXCxcITvd4l{KEG|c3H5 NEn2cXM{NzdwNT:xOUDPxGdxbXy= M4S2fFQ5KGh? MnnQdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> MWCyN|cxQDZ4OB?=
HCT116 NXX4bGVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LZVlAuOTByIN88[{9udA>? MY[0PEBp NFTkSHFqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M33GXFI{PTF6MkCx
NCM460 NHv4[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH6OWhWOC1zMECg{txoN22u MX20PEBp NUjibFBPcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NUTyVFM6OjN3MUiyNFE>
NT2  NVvHO2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjveWozPCCqwrC= MXjMSFUxRTRyMPMAjeK2\y:vbB?= NH\TWVYzOzN6NkSyNC=>
NT2  MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOS2lVPDhiaB?= M1vEcmxFPTB;MUCwJOK2\y:vbB?= M1nUOlI{Ozh4NEKw
NT2  NIq0e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hhb|czKGh? NYHFWIE5VER3ME2yNQKBkcL3Zz;tcC=> MkTFNlM{QDZ2MkC=
NT2  Mn3VRZBweHSxc3nzJGF{e2G7 M4nTW|QxOOLCidM1[{9udA>? MorKNlQhcMLi NHvTSZlqdmS3Y3XzJJNq\26rZnnjZY51KGmwY4LlZZNmeyCrbjDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? NF7hNWYzOzN6NkSyNC=>
NTera-2 NUPTcGs3TnWwY4Tpc44hSXO|YYm= M2nJUVEzOCEQvHevcYw> NIrkN3c4OiCq M4mwXZNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NYfvRmdzOjJ6MkWzOVU>
NCCIT NHzrOZFHfW6ldHnvckBCe3OjeR?= MWWxNlAh|rypL33s MW[3NkBp Mlzod4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= MoL6NlI5OjV|NUW=
NTera-2 MWDGeY5kfGmxbjDBd5NigQ>? MlzINVIxKM7:Zz;tcC=> NGSyT|k4OiCq MVfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCWQlHSV{Bt\X[nbIO= MYSyNlgzPTN3NR?=
NCCIT NGfONG1HfW6ldHnvckBCe3OjeR?= M1vo[VEzOCEQvHevcYw> MWi3NkBp Mn3td4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz Ml;PNlI5OjV|NUW=
NCCIT MkjrSpVv[3Srb36gRZN{[Xl? NWP5dVZuOTJyIN88[{9udA>? M4nPXVczKGh? MUPzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCJU1igcIV3\Wy| NWPDcJdQOjJ6MkWzOVU>
NTera-2 M2PJN2Z2dmO2aX;uJGF{e2G7 MVmxNlAh|rypL33s M2XMdlczKGh? NWSxV3Fbe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? NGHLSWozOjh{NUO1OS=>
NCCIT M4XlemZ2dmO2aX;uJGF{e2G7 M3flN|EzOCEQvHevcYw> NUXiXll6PzJiaB?= NXfLVFJYe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? MkHINlI5OjV|NUW=
NTera-2 MWjGeY5kfGmxbjDBd5NigQ>? M3HxSVEzOCEQvHevcYw> NHT2c|Q4OiCq MlzUd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= M3jRZVIzQDJ3M{W1
NCCIT MWnGeY5kfGmxbjDBd5NigQ>? NWXjTHVkOTJyIN88[{9udA>? MXq3NkBp NGK2XHN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MnfMNlI5OjV|NUW=
MDA-MB-468 NVnmbpoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPVNQKBmzJyMNMg{txoN22O NXXHbZk1OjRiaB?= NHS5T45qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{mzRVIzQDF7MUm2
231-H2N NUnvV4F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmw5qCUOjBywrFOwIcwdUx? NHSyUoEzPCCq Mn3GbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M{HUR|IzQDF7MUm2
A549  MYXGeY5kfGmxbjDBd5NigQ>? M1LwVlIxOC92MECg{txO MnOzdoV{fWy2czDpckBiKGSxc3WtdoV{eG:wc3n2[UBqdmO{ZXHz[UBqdiCUT2O= M133PFIzPzd|Nkm3
A549  M1\uNGZ2dmO2aX;uJGF{e2G7 M2PVcFAuPDByIN88US=> MojCNk01QCCq NH\FcWhk[XW|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl MVuyNlc4OzZ7Nx?=
A549  NHjYeXZHfW6ldHnvckBCe3OjeR?= MWGxNFAh|ryPwrC= NWfLXI9JOOLCk{S4JIg> MYrjZZV{\XNiY3HzdIF{\S1|IHHjeIl3[XSrb36= M4\6bVIzPzd|Nkm3
A549  MnztSpVv[3Srb36gRZN{[Xl? NUPafZZNOTByIN88UeKh NVr2SWVbOOLCk{S4JIg> MWLjZZV{\XNiUFvENUBkdGWjdnHn[S=> M2PSNVIzPzd|Nkm3
A549  M3L4RWZ2dmO2aX;uJGF{e2G7 MYixNFAh|ryPwrC= NWmzOmR{OOLCk{S4JIg> MWHjZZV{\XNibXn0c4Npd26mcnnhcEBtd2OjbHn6ZZRqd25ib3[gRoF5 MVSyNlc4OzZ7Nx?=
A549  M2LRO2Z2dmO2aX;uJGF{e2G7 M1z3e|ExOCEQvF5CpC=> NFPXeHUx6oDVNEigbC=> NF;DPGRl\WO{ZXHz[ZMhVU2SIHHu[EBCXFBibHX2[Yx{ Mn3oNlI4PzN4OUe=
MCF-7/Her-18  M4HYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDkU3d3OC52Mj2xO|AxKM7:Zz;tUC=> NYXzN3YyOjRiaB?= MlfqbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MoGzNlI3OjF2MES=
MCF-7 MVrQSHQwWEOLIGTy[YF1dWWwdB?= M3S5T|AvOjVizsznM41tNg>? MWGxMVQhcA>? Mn65d4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MVqyNlU6OTJ6NB?=
MDA-MB-231 NU\3NZMyWESWL2DDTUBVemWjdH3lcpQ> MVuwMlI2KM7:Zz;tcE4> NYf4WnkzOS12IHi= MWfzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 M{LqRVIzPTlzMki0
MDA-MB-235  M{O4O3BFXC:SQ1mgWJJm[XSvZX70 MXuwMlI2KM7:Zz;tcE4> M4Hse|EuPCCq NHyyepV{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 MmjCNlI2QTF{OES=
MCF-7 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofGNE0zKM7:Zz;tcE4> NUj3VI5vOjRxNEigbC=> M4PFSmVEPTB;MT6yJO69\y:vTB?= M3q4blIzPTlzMki0
NCCIT  M3\URmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP5NlDjiJNzNEFCpO69\y:vbB?= NVjGU3V[PzJiaB?= MX;MSFUxRTF{MNMg{txoN22uwrC= MUeyNlU3OjF4MB?=
NCCIT  MlnESpVv[3Srb36gRZN{[Xl? NUnOd3oxPzJiaB?= MmfXd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NVfqTHlMOjJ3NkKxOlA>
NCCIT  M2DvU2Z2dmO2aX;uJGF{e2G7 NILycVU4OiCq NX3WdmNle2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFkfGm4aYT5xsA> NYGzVoJ7OjJ3NkKxOlA>
NCCIT  M33jNWZ2dmO2aX;uJGF{e2G7 NY\5SIpbPzJiaB?= M4Lz[ZNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg NWXZSYF2OjJ3NkKxOlA>
NCCIT  Mn75SpVv[3Srb36gRZN{[Xl? M1KyZVczKGh? NXrqd3ZNe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgRmFZKGyndnXs MlHaNlI2PjJzNkC=
NCCIT  M{fSW2Z2dmO2aX;uJGF{e2G7 NEf1cng4OiCq Mnq2d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? NH;a[WIzOjV4MkG2NC=>
NCCIT  MnPkSpVv[3Srb36gRZN{[Xl? NFHn[HY4OiCq MoC0d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt M{PBc|IzPTZ{MU[w
HeLa NXLWXVlsTnWwY4Tpc44hSXO|YYm= M3\JfVMxNzdyIN88[{9udA>? MonwNlTDqGh? M2W1OIlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 M{npbFIzPDh5OUO3
MCF-7  MmOxSpVv[3Srb36gRZN{[Xl? NF7zOlc{OC95MDFOwIcwdWx? MonyNlTDqGh? M2O4Rolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 NWf0[W42OjJ2OEe5N|c>
HeLa NWfnWZE1S3m2b4TvfIlkcXS7IFHzd4F6 M3rTXlMxNzdyIN88[{9udA>? MlX4NlTDqGh? MYHpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? MUmyNlQ5Pzl|Nx?=
MCF-7  MmHUR5l1d3SxeHnjbZR6KEG|c3H5 MWezNE84OCEQvHevcYw> MlvxNlTDqGh? NV\YeopGcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NU\TXJNmOjJ2OEe5N|c>
NT2 NUTJVVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNFAuPjBywrFOwIcwdWx? M{PTdVI1KGh? NHyxSZNKSzVyPUSwNEDDvWdxbXy= MmH2NlI1Pjl7NUK=
NT2 NW\BcIZlTnWwY4Tpc44hSXO|YYm= MVe0NFDDqM7:Zz;tcC=> MViyOEBp NVnCb3FCe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zMFgtQSCjY4Tpeol1gcLi MnfLNlI1Pjl7NUK=
NT2 NX3SXZNVTnWwY4Tpc44hSXO|YYm= Mnq2OFAxyqEQvHevcYw> NV;pdWtMOjRiaB?= NFGwd2F{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDCRXghdGW4ZXy= NIGxXGczOjR4OUm1Ni=>
NT2 NYexflF1TnWwY4Tpc44hSXO|YYm= NEHuSms1ODEEoN88[{9udA>? MVWyOEBp NXPZdYdFe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRoNtNTJibHX2[Yw> NV:4Z5FqOjJ2Nkm5OVI>
CHO M3exN2Z2dmO2aX;uJGF{e2G7 M2TUTFIvPcLizsznM41t NFnJZZYyQCCqL{[g[C=> NFjBRoJqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= M3TIN|IzOjNyMUm1
Jurkat M4W3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DnOVAuOTBywrFOwIcwdWx? MorGNlQhcA>? MUfhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> MmXqNlIzOjN|M{K=
Jurkat NVzhWoF{TnWwY4Tpc44hSXO|YYm= NGm4TYw{OMLizsznM41t M3LpeVI1KGh? M{L2[Ilv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiY4njcIlveyCGMzygRUBidmRiQkG= NV3FPZp3OjJ{MkOzN|I>
Jurkat MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfkTJQxNTFyMNMg{txoN22u NF\jV4wzPCCq MVvpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKge4l1cCCjbjDJR|UxKH[jbIXlJI9nKDFyMN88[{9uVA>? NUTX[21EOjJ{MkOzN|I>
Jurkat M{Dhd2Z2dmO2aX;uJGF{e2G7 MUWzNOKh|rypL33s MVOyOEBp MnHvbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? NI\QfGgzOjJ{M{OzNi=>
U2OS EGFPnls NYHz[nhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fv[lAuOsLizsznM41t NECyZVkzPCCq NGDLfZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NHTXWJUzOThzMUCwOy=>
U2OS KuEnls NF;kSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLGNE0zyqEQvHevcYw> Mo[0NlQhcA>? MoH6bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4OxflIyQDFzMEC3
MCF-7 NWeyW28{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:wMVQxOCEQvF2= NFLDdnQ4OiCq NFn1SnBNSzVyPUG1NU45yqEQvF2= MmDMNlE4ODN{OUG=
MCF-7/Adr  Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvlVW51OC12MECg{txO NFzIS5E4OiCq MUnMR|UxRTV6LkZCpO69VcLi NGDHNmkzOTdyM{K5NS=>
WI-38 M3\1d2Z2dmO2aX;uJGF{e2G7 MUSwM|QxNzhy4pEJ{txoN22uwrC= NWrnOXFMOyCq M3\Zc4lv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MUiyNVU6QTZzMh?=
hBMSC MoXFSpVv[3Srb36gRZN{[Xl? MV6wM|QxNzhy4pEJ{txoN22uwrC= NHTEXW0{KGh? Mmm0bY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NXLwTVIxOjF3OUm2NVI>
NCI-H23 NFnzToJHfW6ldHnvckBCe3OjeR?= MU[wM|QxNzhy4pEJ{txoN22uwrC= NHTYU2Y{KGh? NIDDdYVqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NIXlc5YzOTV7OU[xNi=>
A-549 MnzDSpVv[3Srb36gRZN{[Xl? M{HmTlAwPDBxOEFihKnPxGdxbX|CpC=> MUezJIg> NILmUJpqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MkHGNlE2QTl4MUK=
PBL  MlPLSpVv[3Srb36gRZN{[Xl? M4LMOlAwPDBxOEFihKnPxGdxbX|CpC=> MlnqN{Bp MXzpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg M3;OcVIyPTl7NkGy
pol β −/− M4rJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;yclYxNjJ3LUKwNOKh|rypL33s MkjMNlTDqGh? M2HFVIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bZRpKGmwY4LlZZNqdmdiY3;uZ4VvfHKjdHnvcpPDqA>? NVXGUnRKOjF{NUG5OFQ>
pol β +/+ NVHrdZlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiwMlI2NTJyMNMg{txoN22u M2TVS|I1yqCq MojR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh MY[yNVI2OTl2NB?=
pol β −/− NEPWVI1HfW6ldHnvckBCe3OjeR?= NF\5PWIxNTJwNTFOwIcwdWx? MXGyJIg> MYXjZZV{\XNiRF7BJIRidWGpZR?= NFflXJczOTJ3MUm0OC=>
pol β +/+ MojpSpVv[3Srb36gRZN{[Xl? MX6wMVIvPSEQvHevcYw> NU\6PGxCOiCq NFvu[IJk[XW|ZYOgSG5CKGSjbXHn[S=> NYfST5NLOjF{NUG5OFQ>
pol β −/− NED2fVJHfW6ldHnvckBCe3OjeR?= NHzJSIQxNTVizsznM41t NInuflY1QCCq NEHV[mFk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NGXFWVYzOTJ3MUm0OC=>
pol β +/+ MnnhSpVv[3Srb36gRZN{[Xl? MVqwMVUh|rypL33s MoXmOFghcA>? M{W2e4NifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> M{TYZlIyOjVzOUS0
TK6  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYiyOU0yPTBizsznM41t M{XXPFk3KGh? MnHLbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYDjeGRROjFyOEG0PFc>
TK6  sLUC+Apn1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\xNlUuOTVyIN88[{9udA>? NFjDUY86PiCq MmPwbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Moj6NlExQDF2OEe=
TK6 sAPE1+Apn1 M1SxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\jOYtSOjVvMUWwJO69\y:vbB?= MVK5OkBp NXvTRXJye2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MmDMNlExQDF2OEe=
HCT116 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn61NlUuOTVyIN88[{9udA>? M3zKclk3KGh? MWHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Mlu4NlExQDF2OEe=
HCT116 sLUC+Apn1 NVvS[GZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDO[GMzPS1zNUCg{txoN22u M1;0UVk3KGh? NYrvUoZ3cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Moi4NlExQDF2OEe=
HCT116 sAPE1+Apn1 M3HIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnsVllHOjVvMUWwJO69\y:vbB?= NFHE[2U6PiCq MkXod4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 Mn\GNlExQDF2OEe=

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How about the strength of Bleomycin Sulfate(S1214) in terms of Units/mg?

  • Answer:

    Our S1214 Bleomycin Sulfate is 1500 Units/mg.

  • Question 2:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID